TABLE 3.
CPNDS PGx testing panel for antibiotics, analgesics and mental health drugs
| Drugs | Adverse drug reactions | Genes | Rationale | ||
|---|---|---|---|---|---|
| ANTIBIOTICS PGx PANEL | |||||
| Aminoglycosides | Hearing loss, deafness | MT‐RNR1 | |||
| Dapsone/sulfonamides | Haemolytic anaemia | G6PD | |||
| Rifampin/isoniazid/pyrazinamide | Serious liver injury | NAT2 | |||
| ANALGESICS PGx PANEL | |||||
| Codeine | CNS depression, therapeutic failure, death | CYP2D6 | |||
| Hydrocodone | CYP2D6 | ||||
| Oxycodone | CNS depression, death | CYP2D6 | |||
| Tramadol | CYP2D6 | ||||
| MENTAL HEALTH PGx PANEL | |||||
| Mood disorders | |||||
| Carbamazepine | Severe cutaneous reactions | HLA‐B, HLA‐A | |||
| Phenytoin | HLA‐B, CYP2C9 | ||||
| ADHD | |||||
| Atomoxetine | Therapeutic failure | CYP2D6 | |||
| Antidepressants | |||||
| SSRIs (e.g., paroxetine) | Therapeutic failure | CYP2D6, CYP2C19 | |||
| SNRIs (e.g., venlafaxine) | CYP2D6 | ||||
Abbreviations: PGx, pharmacogenomics; SNRI, serotonin‐norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitors.